Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 454 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle solution Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951
View directory record Official record
Conditions
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
3 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

NCT03019627
View directory record Official record
Conditions
Dry Eye
Interventions
NGF, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04201574
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ALY688 0.1%, ALY688 0.4%, Vehicle
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

NCT01737762
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

NCT01639846
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
RX-10045, Vehicle for RX-10045 arm
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

NCT05665387
View directory record Official record
Conditions
Presbyopia
Interventions
0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
47 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Morrow, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02081703
View directory record Official record
Conditions
Postsurgical Pain
Interventions
AYX1 Injection 660 mg / 6 mL, AYX1 Injection 1100 mg / 10 mL, Placebo Injection 6 mL, Placebo Injection 10 mL
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Sheffield, Alabama • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Early Phase 1 Interventional

Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)

NCT02710110
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PowerLung trainer, Micro Mouth Pressure Meter, Pulmonary Function Testing, Videofluoroscopic swallowing study, Swallowing Quality of Life Questionnaire, Iowa Oral Pressure Instrument, Capsaicin
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920
View directory record Official record
Conditions
Seborrheic Keratosis (SK)
Interventions
A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

NCT01488019
View directory record Official record
Conditions
COPD
Interventions
Perforomist-Placebo, Perforomist, nebulization, COPD
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
AR-12286, AR-12286 vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04475432
View directory record Official record
Conditions
Blepharitis
Interventions
TP-03, 0.25%, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Study of AR-13324 in Patients With Elevated Intraocular Pressure

NCT01528787
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
11
States / cities
Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT01731730
View directory record Official record
Conditions
Postsurgical Pain
Interventions
Placebo Injection, AYX1 Injection 110 mg, AYX1 Injection 330 mg
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 19, 2026, 5:26 PM EDT
Completed No phase listed Observational

Delineating Swallowing Impairment and Decline in ALS

NCT02962050
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Videofluoroscopic Swallowing Study (VFSS), Voluntary Peak Cough Flow Testing, Iowa Oral Performance Instrument, Capsaicin Challenge, Pulmonary Function Testing, Eating Assessment Tool 10, The Center for Neurologic Study Bulbar Function Scale
Procedure · Device · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 19, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pain and Acetaminophen in Women Study

NCT04573426
View directory record Official record
Conditions
Overweight, Obesity, Healthy Adults
Interventions
Acetaminophen, Placebo, Weight stigma vignette, Control vignette
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 19, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ibuprofen 5% Topical Gel CIPT

NCT01771822
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 5% topical gel, Topical gel vehicle, Sodium lauryl sulfate 0.2%, Sodium chloride solution 0.9% (saline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Carlstadt, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 19, 2026, 5:26 PM EDT